Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Lucid Diagnostics Inc (NASDAQ: LUCD) closed the day trading at $1.01 down -6.48% from the previous closing price of $1.08. In other words, the price has decreased by -$6.48 from its previous closing price. On the day, 1.38 million shares were traded. LUCD stock price reached its highest trading level at $1.11 during the session, while it also had its lowest trading level at $1.0.
Ratios:
For a better understanding of LUCD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.72 and its Current Ratio is at 0.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ascendiant Capital Markets on December 27, 2021, initiated with a Buy rating and assigned the stock a target price of $16.
On November 08, 2021, Needham started tracking the stock assigning a Buy rating and target price of $17.
On November 08, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $21.Cantor Fitzgerald initiated its Overweight rating on November 08, 2021, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Matheis Dennis bought 187,098 shares for $1.29 per share. The transaction valued at 242,292 led to the insider holds 187,098 shares of the business.
Matheis Dennis bought 129,684 shares of LUCD for $171,520 on May 21 ’25. The Director now owns 316,782 shares after completing the transaction at $1.32 per share. On May 22 ’25, another insider, Matheis Dennis, who serves as the Director of the company, bought 33,218 shares for $1.32 each. As a result, the insider paid 43,795 and bolstered with 350,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUCD now has a Market Capitalization of 109276952 and an Enterprise Value of 166244784. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.21. Its current Enterprise Value per Revenue stands at 39.838 whereas that against EBITDA is -3.548.
Stock Price History:
The Beta on a monthly basis for LUCD is 1.22, which has changed by 0.26250005 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, LUCD has reached a high of $1.80, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -16.77%, while the 200-Day Moving Average is calculated to be -10.59%.
Shares Statistics:
Over the past 3-months, LUCD traded about 1.22M shares per day on average, while over the past 10 days, LUCD traded about 867380 shares per day. A total of 84.37M shares are outstanding, with a floating share count of 40.34M. Insiders hold about 62.71% of the company’s shares, while institutions hold 9.94% stake in the company. Shares short for LUCD as of 1752537600 were 4790040 with a Short Ratio of 3.93, compared to 1749772800 on 1656077. Therefore, it implies a Short% of Shares Outstanding of 4790040 and a Short% of Float of 6.69.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Lucid Diagnostics Inc (LUCD) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.41 and -$0.46 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.31, with 3.0 analysts recommending between -$0.25 and -$0.36.
Revenue Estimates
6 analysts predict $1.15M in revenue for the current quarter. It ranges from a high estimate of $1.45M to a low estimate of $900k. As of the current estimate, Lucid Diagnostics Inc’s year-ago sales were $976kFor the next quarter, 6 analysts are estimating revenue of $1.89M. There is a high estimate of $2.6M for the next quarter, whereas the lowest estimate is $1M.
A total of 6 analysts have provided revenue estimates for LUCD’s current fiscal year. The highest revenue estimate was $8.8M, while the lowest revenue estimate was $4M, resulting in an average revenue estimate of $6.29M. In the same quarter a year ago, actual revenue was $4.35MBased on 6 analysts’ estimates, the company’s revenue will be $18.97M in the next fiscal year. The high estimate is $37M and the low estimate is $10M.
